Beckmann Model
1. Description
Beckmann Model is a simple multi-criteria model, which scores benefits and risks in three aspects.[1][2]The scoring system for benefits is:
The scoring system for risk is:
2. Evaluation
2.1 Principle
- Beckmann Model does not take into account the relative importance of benefit and risk criteria.
- It does not integrate benefit and risk.
- The model does not readily incorporate statistical uncertainty in input data into the analysis due to its category scoring system.
2.2 Features
- It deals with benefits and risks separately without integrating them into a single measure.
- The only weight in the model is driven by the 'evidence' parameters, which weigh the benefit and risk scores.
- Other criteria within the benefit and risk scores are not weighted.
2.3 Visualisation
- Visualisations similar to the one used in Principle of Threes may be used.
2.4 Assessability and accessibility
- The analysis is simple.
- It does not take into account stakeholder's value preferences.
- It may be useful for quick initial assessments.
3. References
[1] Beckmann J. Basic aspects of risk-benefit analysis. Semin Thromb Hemost 1999;25(1):89-95.
[2] Mussen F, Salek S, Walker S. Review of the Current Benefit-Risk Assessment Models. Benefit-Risk Appraisal of Medicines. 1 ed. John Wiley & Sons, Ltd.; 2009. p. 63-97.
- Beckmann Model does not take into account the relative importance of benefit and risk criteria.
- It does not integrate benefit and risk.
- The model does not readily incorporate statistical uncertainty in input data into the analysis due to its category scoring system.
2.2 Features
- It deals with benefits and risks separately without integrating them into a single measure.
- The only weight in the model is driven by the 'evidence' parameters, which weigh the benefit and risk scores.
- Other criteria within the benefit and risk scores are not weighted.
2.3 Visualisation
- Visualisations similar to the one used in Principle of Threes may be used.
2.4 Assessability and accessibility
- The analysis is simple.
- It does not take into account stakeholder's value preferences.
- It may be useful for quick initial assessments.
3. References
[1] Beckmann J. Basic aspects of risk-benefit analysis. Semin Thromb Hemost 1999;25(1):89-95.[2] Mussen F, Salek S, Walker S. Review of the Current Benefit-Risk Assessment Models. Benefit-Risk Appraisal of Medicines. 1 ed. John Wiley & Sons, Ltd.; 2009. p. 63-97.